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ABSTRACT
Ceftobiprole is a novel, broad-spectrum cephalosporin with in-vitro activity against common Gram-
positive and Gram-negative organisms. It forms a stable inhibitory complex with Staphylococcus aureus
penicillin-binding protein (PBP) 2¢ (2a), resulting in enhanced activity against methicillin-resistant
S. aureus (MRSA). In recent studies of methicillin-susceptible S. aureus, the ceftobiprole MIC90 value was
most frequently £1.0 mg ⁄L (MIC range £0.25–1.0 mg ⁄L). For MRSA, MIC90 values were generally
2.0 mg ⁄L (MIC range £0.06–4.0 mg ⁄L). MICs for all streptococcal species, except penicillin-resistant
Streptococcus viridans but including penicillin-resistant Streptococcus pneumoniae, ranged from £0.008 to
2.0 mg ⁄L. Ceftobiprole is active against Enterococcus faecalis (MIC90 ¼ 4 mg ⁄L), but not generally active
against Enterococcus faecium (MIC90 > 16 mg ⁄L). Ceftobiprole displayed bactericidal activity against
Gram-negative pathogens comparable to that of cefepime, ceftazidime or piperacillin–tazobactam in
early studies. However, recent data show activity against Pseudomonas aeruginosa similar to that of
cefepime but less than that of ceftazidime. Ceftobiprole, like cefepime, is stable in the presence of most
class A non-extended spectrum b-lactamases and inducible class C b-lactamases. Ceftobiprole is a poor
inducer of AmpC b-lactamase and a poor substrate for hydrolysis by AmpC b-lactamase. Studies of
ceftobiprole in several animal models have demonstrated potent in-vivo efficacy against infections
caused by MRSA, including strains intermediately resistant to vancomycin. It was also efficacious in
murine infections caused by Gram-negative bacteria with MIC values £2 mg ⁄L. The broad spectrum of
activity demonstrated by ceftobiprole in vitro and in vivo suggests that it may have potential for
empirical treatment of suspected Gram-negative and Gram-positive infections, including those caused
by MRSA.
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INTRODUCTION
Ceftobiprole is a novel cephalosporin with broad-
spectrum activity against most clinically relevant
bacterial pathogens, including methicillin-resist-
ant Staphylococcus aureus (MRSA). This bactericidal
agent, delivered as a prodrug, ceftobiprole me-
docaril, has recently been shown to be clinically
and microbiologically effective on the basis of
preliminary data from phase III clinical studies [1].
The availability of antibiotics with anti-MRSA
activity is critical because the prevalence of MRSA
infections is increasing worldwide. Surveillance
data from the TSN Database USA (Eurofins
Medinet, Inc.) illustrate this growing prevalence
in the USA among inpatients, and especially those
in the intensive care unit. For example, among the
sub-population aged 64 years or more, the pro-
portion of MRSA isolates has increased over the
past decade and now comprises 60–70% of all
isolates (Fig. 1). The percentage of outpatients
with infections caused by MRSA has also in-
creased and directly correlates with the rate of
MRSA infection among inpatients at a given
hospital [2]. This signifies that MRSA is no longer
confined to hospitals but is also a problem within
the community, especially in so-called healthcare-
associated infections.
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Ceftobiprole is a novel member of the cephalo-
sporin family of antibiotics with demonstrated
activity against MRSA. The cephalosporins have
played a critical role in healthcare since 1953, and
the clinical utility of this class has evolved with
each new generation or group. For example,
cefotaxime, ceftriaxone and cefuroxime, classified
as group 4 cephalosporins according to the Bry-
skier system [3], are broad-spectrum compounds
but lack activity against the non-fermenting Gram-
negative organisms, and are hydrolysed slowly by
AmpC b-lactamases produced by some entero-
bacteriaceae. By comparison, the more recently
developed cephalosporins cefepime and cefpirom-
e, classified as group 6, have an extended spectrum
of activity, including Pseudomonas aeruginosa, and a
lower affinity for chromosomal b-lactamases.
These properties result in a marked advantage
against resistant mutants of several species pro-
ducing either derepressed class C chromosomal
b-lactamases or variant class A b-lactamases [4].
Because of these qualities and their history of
safety and tolerability, cephalosporins are themost
widely used class of antibiotic in the hospital
setting. However, all currently available b-lactam
antibiotics are considered to be clinically inactive
against MRSA [5].
Ceftobiprole has not yet been classified accord-
ing to the Bryskier system. Nevertheless, its
bactericidal activity against MRSA and Enterococ-
cus faecalis, at concentrations that are therapeutic-
ally achievable, sets it apart from other
cephalosporins, signifying potential clinical util-
ity, especially during this time of increasing
MRSA prevalence. The potent anti-MRSA activity
of ceftobiprole is attributable to a mechanism of
action similar to that of all other b-lactam mole-
cules; that is, ceftobiprole prevents formation of a
new cell wall in dividing bacteria, eventually
leading to cell lysis, through binding and inhib-
iting penicillin-binding proteins (PBPs). The crit-
ical differentiating feature of ceftobiprole is its
apparent high-affinity interaction with PBP2¢ (2a)
of methicillin-resistant staphylococci, the PBP that
is responsible for resistance to other b-lactam
antibiotics [6].
IN-VITRO ACTIVITY AGAINST
GRAM-POSITIVE COCCI
Ceftobiprole exhibits potent bactericidal activity
in vitro against most clinically relevant strepto-
cocci and staphylococci, including penicillin-
resistant strains of pneumococcus and MRSA.
In-vitro susceptibility of staphylococci to ceftobi-
prole has been evaluated in a number of different
studies (Table 1) [6–9] (15th ECCMID, abstract
70
60
50
40
30
20
10
0
%
 o
f i
so
la
te
s
1996 1997 1998 1999 2000 2001 2002
MSSA MRSA
2003 2004 2005
Year
Fig. 1. Prevalence of methicillin-
resistant Staphylococcus aureus
(MRSA) in the USA among clinical
specimens from inpatients ⁄ intensive
care unit patients aged >64 years
(n ¼ approximately 4000–38 000
isolates per year) (TSN Database
USA, Eurofins Medinet, Inc.).
Table 1. Summary of in-vitro susceptibility of staphylo-
cocci to ceftobiprole
Staphylococci
tested Total
MIC
range
(mg ⁄L)
MIC90
(mg ⁄L)
MRSAa,b [8,9] 925 0.06–2 2
MSSAa [8,9] 248 0.25–2 0.5
VISA [8] 18 0.25–4 –
VRSA [7,8] 2 2 –
MSCoNSa [8,9] 72 £0.015–1 1
MRCoNSa [8,9] 327 £0.015–8 2
a44th ICAAC, abstract E-2021).
b15th ECCMID, abstract P-1570.
MRSA, methicillin-resistant Staphylococcus aureus; MSSA,
methicillin-susceptible S. aureus; VISA, intermediately
vancomycin-resistant S. aureus; VRSA, vancomycin-resist-
ant S. aureus; MSCoNS, methicillin-susceptible ⁄ coagulase-
negative staphylococci; MRCoNS, methicillin-suscept-
ible ⁄ coagulase-negative staphylococci.
18 Clinical Microbiology and Infection, Volume 13 Supplement 2, 2007
 2007 The Author
Journal Compilation  2007 Clinical Microbiology and Infectious Diseases, CMI, 13 (suppl 2), 17–24
P-1570). On the basis of cumulative data from
these studies, MICs for methicillin-susceptible
S. aureus (MSSA) strains (n ¼ 248) had a distri-
bution of 0.25–2 mg ⁄L, and the MIC90 was
0.5 mg ⁄L. Given the importance of MRSA, the
activity of ceftobiprole was measured against an
even greater number of isolates, totalling 925.
MIC values ranged from 0.06 mg ⁄L to 2 mg ⁄L,
with an MIC90 of 2 mg ⁄L. Because 100% of MRSA
isolates were susceptible at MIC values of
£4 mg ⁄L, ceftobiprole has demonstrated greater
in-vitro activity against this resistant pathogen
than all currently marketed b-lactams.
These results are supported by an ongoing
study of ceftobiprole activity against recent clin-
ical isolates of S. aureus obtained from patients
with complicated skin and skin structure infec-
tions (44th ICAAC, abstract E-2021). Among the
230 MRSA isolates from this trial, the MIC
distribution was 0.5–2 mg ⁄L. The MIC distribu-
tion of more than 300 MSSA was 0.12–1 mg ⁄L.
Ceftobiprole is also effective against other
Staphylococcus strains with reduced susceptibility
to commonly used antibiotics [6–9] (15th ECC-
MID, abstract P-1570). Resistance to the glyco-
peptide vancomycin, an important anti-MRSA
drug, has now been reported in isolated patients
[10,11]. MIC distributions of ceftobiprole against
18 intermediately vancomycin-resistant S. aureus
isolates (0.25–4 mg ⁄L) and two vancomycin-
resistant S. aureus isolates (2 mg ⁄L) are similar
to those of vancomycin-susceptible MRSA isolates
(Table 1) [8], suggesting that decreased suscepti-
bility to vancomycin has a negligible effect on
ceftobiprole activity. Activity against coagulase-
negative staphylococci has also been evaluated,
since these bacteria are a major cause of nosocomial
infections and are often resistant to multiple anti-
biotics. The MIC distribution for methicillin-sus-
ceptible ⁄ coagulase-negative staphylococci strains
was £0.015–1 mg ⁄L (MIC90 ¼ 1 mg ⁄L), and for
methicillin-resistant ⁄ coagulase-negative staphylo-
cocci it was £0.015–8 mg ⁄L (MIC90 ¼ 2 mg ⁄L)
(Table 1).
The anti-MRSA activity of ceftobiprole has been
compared to that of other agents in a number of
studies [6–9] (44th ICAAC, abstract E-2021). On
the basis of MIC90 values, ceftobiprole has anti-
staphylococcal activity similar to that of vanco-
mycin and linezolid (MIC90 ¼ 2 mg ⁄L for all three
agents) and activity superior to that of ciprofloxa-
cin and erythromycin (both MIC90 > 32 mg ⁄L),
clindamycin (MIC90 ¼ 16 mg ⁄L) and other b-lac-
tams (MIC90 > 32 mg ⁄L for cefotaxime, ceftriax-
one, cefepime, and meropenem). The bactericidal
activity of ceftobiprole against S. aureus, based on
the killing rate against S. aureus ATCC 25923, is
shown in Fig. 2. Bactericidal activity measured
over 24 h was rapid at 0.5–5.0 · MIC [6]. Vanco-
mycin compared less favourably, demonstrating
bactericidal activity after 24 h only at 5.0 · MIC.
The broad-spectrum activity of ceftobiprole
also encompasses streptococci, including strains
of Streptococcus pneumoniae and enterococci. With
regard to enterococci, ceftobiprole activity is
similar to that of other cephalosporins. MIC
values ranged from 0.12 to 2 mg ⁄L for 33 Entero-
coccus faecalis isolates, including ampicillin-sus-
ceptible, vancomycin-resistant Enterococcus faecalis
strains (44th ICAAC, abstract E-2021). However,
0.5 MIC 2.0 MIC 5.0 MIC1.0 MICControl
1.00E+02
1.00E+03
1.00E+04
1.00E+05
1.00E+06
1.00E+07
1.00E+08
1.00E+10
1.00E+09
CF
U/
m
L
0 2 4 6 8 24
Vancomycin
Time (h)
1.00E+02
1.00E+03
1.00E+04
1.00E+05
1.00E+06
1.00E+07
1.00E+08
1.00E+10
1.00E+09
CF
U/
m
L
0 1 2 4 6 8 24
Ceftobiprole
Time (h)
Fig. 2. The bactericidal activities
of ceftobiprole and vancomycin
against methicillin-susceptible
Staphylococcus aureus ATCC 25923
over 24 h. Reproduced from
Hebeisen et al. [6] with permission.
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ceftobiprole generally demonstrated poor activity
against Enterococcus faecium, with MIC values of 2
or >8 mg ⁄L for a small number of tested isolates
[12].
Activity against S. pneumoniae, including peni-
cillin-resistant strains, was demonstrated in a
study of 299 clinical isolates [13] using agar
dilution to determine MIC values against penicil-
lin-susceptible, intermediately penicillin-resistant
and penicillin-resistant strains. Ceftobiprole had
the lowest MIC90 values compared to other b-
lactams tested, including cefepime, ceftriaxone,
penicillin and amoxycillin (Fig. 3). MIC90 values
for ceftobiprole were 0.016 mg ⁄L for penicillin-
susceptible strains (MIC distribution 0.008–
0.03 mg ⁄L), 0.5 mg ⁄L for penicillin-intermediate
strains (0.008–1 mg ⁄L), and 1 mg ⁄L for penicillin-
resistant strains (0.016–4 mg ⁄L). By comparison,
MIC90 values for the other b-lactams against
penicillin-resistant strains were 2–8 times higher
(2 mg ⁄L, cefepime and ceftriaxone; 16 mg ⁄L,
cefuroxime; 4 mg ⁄L, penicillin; and 8 mg ⁄L, am-
oxycillin). Thus, ceftobiprole had the lowest MIC
values among the six b-lactams tested against
pneumococci and was active against strains
resistant to other agents, including multidrug-
resistant strains.
IN-VITRO ACTIVITY AGAINST
GRAM-NEGATIVE BACILLI
In addition to being active against resistant Gram-
positive pathogens, ceftobiprole demonstrates
activity against clinically important Gram-negat-
ive bacteria. Heep et al. (15th ECCMID, abstract
P-1569) measured in-vitro activity against Entero-
bacteriaceae using 372 clinical isolates from res-
piratory infections among hospitalised patients in
the USA and Europe. Isolates comprised the most
common Enterobacteriaceae species, including
Escherichia coli (n ¼ 60), Serratia marcescens
(n ¼ 62), Klebsiella pneumoniae (n ¼ 60), Enterob-
acter cloacae (n ¼ 60), Enterobacter aerogenes
(n ¼ 17), Citrobacter freundii (n ¼ 20), Citrobacter
koseri (n ¼ 7), Klebsiella oxytoca (n ¼ 25), and
Proteus mirabilis (n ¼ 61). These included strains
that produce extended-spectrum b-lactamases
(ESBLs). MIC values, determined by broth micro-
dilution, were similar for ceftobiprole, ceftazi-
dime and cefepime, with MIC90 values of 4, 32
and 1 mg ⁄L, respectively. At an MIC of 4 mg ⁄L,
ceftobiprole inhibited the growth of 92.2% of the
strains tested.
Fig. 4 illustrates these data as cumulative
percentages of Enterobacteriaceae inhibited at
different cephalosporin MIC values (15th ECC-
MID, abstract P-1569). Inclusion of all 372 iso-
lates (Fig. 4a) clearly shows that the differences
among the three cephalosporins were most
prominent at the lowest MIC values. Cefepime
and ceftobiprole were remarkably similar across
the spectrum of MIC values, whereas ceftazi-
dime MICs consistently resulted in lower cumu-
lative percentages.
Analysis of the sub-population of putative
ESBL or high-level AmpC b-lactamase (299 of
the 372 isolates) non-producers indicated that
ceftobiprole and cefepime had cumulative per-
centages of 100% inhibition across almost the
entire spectrum of MIC values (Fig. 4b). Among
the 21 isolates that were putative AmpC pro-
ducers but not ESBL producers (Fig. 4c), cefep-
ime and ceftobiprole maintained moderate
activity (MIC90 values of 8 mg ⁄L for cefepime
and 32 mg ⁄L for ceftobiprole), unlike ceftazi-
dime, which demonstrated an MIC50 > 32 mg ⁄L.
Sub-analysis of the 42 putative ESBL-producing
isolates showed poor inhibitory activity for all
three cephalosporins (Fig. 4d). Therefore, cefto-
biprole demonstrates antibacterial activity
against the Enterobacteriaceae that resembles
that of cefepime more closely than that of
ceftazidime.
Similar results have been reported by others.
Hebeisen et al. [6] showed high levels of in-vitro
activity for ceftobiprole against ESBL-negative
isolates of Enterobacteriaceae, Haemophilus influ-
enzae, Neisseria gonorrhoeae and Moraxella catarrh-
alis, among others. Susceptibility was comparable
to that of other b-lactams tested.
Ceftobiprole is also active against non-ferment-
ing Gram-negative bacteria, such as P. aeruginosa
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Fig. 3. Comparison of b-lactam MIC values against Strep-
tococcus pneumoniae (n ¼ 300) [13].
20 Clinical Microbiology and Infection, Volume 13 Supplement 2, 2007
 2007 The Author
Journal Compilation  2007 Clinical Microbiology and Infectious Diseases, CMI, 13 (suppl 2), 17–24
and Acinetobacter baumannii. The susceptibility of
P. aeruginosa to ceftobiprole was evaluated in vitro
using collections of recent clinical isolates from
the USA (n ¼ 203) and Europe (n ¼ 204) in
comparison to b-lactams commonly used to treat
pseudomonal infections (43rd IDSA, abstract P-
506). b-Lactam resistance was common within
both collections. MIC90 values against European
isolates were 32 mg ⁄L for ceftobiprole, compared
to >32 mg ⁄L for ceftazidime and >128 mg ⁄L for
piperacillin–tazobactam. Results were similar for
isolates from the USA: MIC90 of 16 mg ⁄L for
ceftobiprole, 32 mg ⁄L for ceftazidime, and
>128 mg ⁄L for piperacillin–tazobactam. Graphi-
cal representations of the cumulative percentages
of P. aeruginosa isolates inhibited over a range of
MIC values show similar profiles for ceftobiprole
and ceftazidime, which are superior to that of
piperacillin–tazobactam (Fig. 5). Similar results
have been obtained in other studies (44th ICAAC,
abstract E-2021) [6,9]. For example, in a recent
study (44th ICAAC, abstract E-2021), ceftobiprole
had MIC90 values against P. aeruginosa isolates
(n ¼ 101) of 16 mg ⁄L (range 1–32 mg ⁄L), as com-
pared to 16 mg ⁄L (range 1 to >65 mg ⁄L) for
cefepime and 32 mg ⁄L (range 1 to >64 mg ⁄L) for
ceftazidime. Like all other b-lactams, ceftobiprole
does not show activity against strains producing
metallo-b-lactamases.
Acinetobacter spp. are also among the Gram-
negative, non-fermenting bacteria commonly iso-
lated from nosocomial infections. In-vitro activity
of ceftobiprole against A. baumannii is potentially
clinically relevant, since MDR strains have been
isolated with increasing frequency in recent years
(44th ICAAC, abstract E-2021). Ceftobiprole activ-
ity was compared to that of other cephalosporins
among isolates obtained during pneumonia clin-
ical trials performed in 1998–2001 (44th ICAAC,
abstract E-2021). Among the 42 A. baumannii
isolates, ceftobiprole activity was superior to that
of other cephalosporins (Fig. 6). Ceftobiprole
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Fig. 4. Cumulative percentages of Enterobacteriaceae isolated from respiratory specimens inhibited at different
cephalosporin MIC values for (a) all clinical isolates (N ¼ 372), (b) only non-ESBL ⁄AmpC producers (n ¼ 299), (c)
putative AmpC producers (n ¼ 21), and (d) putative ESBL producers (n ¼ 42). Isolates tested were Escherichia coli (n ¼ 60),
Serratia marcescens (n ¼ 62), Klebsiella pneumoniae (n ¼ 60), Enterobacter cloacae (n ¼ 60), Enterobacter aerogenes (n ¼ 17),
Citrobacter freundii (n ¼ 20), Citrobacter koseri (n ¼ 7), Klebsiella oxytoca (n ¼ 25) and Proteus mirabilis (n ¼ 61) (15th
ECCMID, abstract P-1569).
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inhibited 79% of isolates at 4 mg ⁄L, compared to
60% for cefepime, 43% for ceftazidime, and 5%
for ceftriaxone. Interestingly, isolates had a bimo-
dal distribution with regard to susceptibility to
ceftobiprole (Fig. 6). One sub-population was
fully susceptible, with MIC values ranging from
0.13 to 1 mg ⁄L. A separate, multidrug-resistant
sub-population had MIC values ranging from 16
to >64 mg ⁄L. This population includes strains
producing multiple b-lactamases, including met-
allo-b-lactamases, to which ceftobiprole is not
stable.
IN-VITRO ACTIVITY AGAINST
ANAEROBES
Ceftobiprole activity against anaerobic bacteria
has also been examined. Some Clostridium species
were found to be relatively susceptible to cefto-
biprole, with MIC90 values of <4 mg ⁄L [9].
Modest activity (MIC50 < 4 mg ⁄L and MIC90
> 4 mg ⁄L) was reported against Gram-positive
anaerobic cocci and species from the following
genera: Actinomyces, Clostridium, Fusobacterium,
Lactobacillus, Porphyromonas, Prevotella, and Veillo-
nella [14]. However, Bacteroides fragilis and other
Bacteroides species were generally resistant to
ceftobiprole [6,9,14].
CEFTOBIPROLE AND B -LACTAM
RESISTANCE
In considering these data with regard to known
b-lactam resistance mechanisms, ceftobiprole has
certain advantages over penicillins and other
extended-spectrum cephalosporins [9] (15th ECC-
MID, abstract P-1569; 45th ICAAC, abstract C1-
55). Most important is that only ceftobiprole is
relatively unaffected by resistance mediated by
acquired or mutated PBPs, judging from its high
binding affinity for S. aureus PBP2¢ and S. pneu-
moniae PBP2x [6,15]. The exception is Enterococcus
faecium PBP5, against which no available b-lactam
is effective.
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Ceftobiprole is also stable in the presence
of certain b-lactamase-mediated resistance
mechanisms. Unlike penicillins, ceftobiprole is
unaffected by Staphylococcus penicillinases and
broad-spectrum b-lactamases (TEM-1 deriva-
tives). Like extended-spectrum cephalosporins,
ceftobiprole appears to have modest stability
against the AmpC b-lactamases, as described
earlier [6]. In addition, Queenan and Bush (45th
ICAAC, abstract C1-55) and Heep et al. (15th
ECCMID, abstract P-1569) demonstrated that
ceftobiprole had a low potential for inducing
chromosomal AmpC b-lactamase and that it was
a poor substrate for hydrolysis by this enzyme in
the Gram-negative isolates tested (Morganella
morganii, Citro. freundii, Providencia stuartii, Ente-
robacter cloacae, S. marcescens, P. aeruginosa), sim-
ilar to cefepime and ceftazidime. However,
ceftobiprole appears to be hydrolysed by most
ESBLs and metallo-b-lactamases, as demonstrated
by Hebeisen et al. [6].
IN-VIVO EFFICACY OF
CEFTOBIPROLE
The efficacy of ceftobiprole against infections
caused by a wide range of pathogens, including
MRSA and other resistant strains, has been
demonstrated in multiple animal models, includ-
ing those mimicking severe systemic infection.
These experimental systems include mouse sep-
ticaemia, subcutaneous abscess and pneumonia
models; rat endocarditis and tissue cage models;
and rabbit endocarditis and osteomyelitis models.
In experimental septicaemia, ceftobiprole activ-
ity was comparable to or better than that of
ceftriaxone, cefepime and meropenem [6]. In-vivo
efficacy, measured as ED50 (dose at which 50% of
animals survived on the fourth day following
infection), correlated well with MIC values deter-
mined in vitro. Ceftobiprole was effective against
numerous clinical strains of MSSA, MRSA, group
A Streptococcus, penicillin-sensitive S. pneumoniae,
and penicillin-resistant S. pneumoniae, with ED50
values ranging from <0.2 to 2.4 mg ⁄L. For non-
ESBL-producing Gram-negative species, ceftobi-
prole had ED50 values ranging from <0.2 to
4.0 mg ⁄L for E. coli, K. pneumoniae, C. freundii,
Enterobacter cloacae, S. marcescens, P. mirabilis,
and P. aeruginosa. Ceftobiprole was inactive
against infections caused by Proteus vulgaris, as
expected due to production of a broad-spectrum
class A cephalosporinase that also hydrolyses
cefepime and ceftriaxone [6,16].
The effectiveness of ceftobiprole was evaluated
in a mouse model of subcutaneous abscesses
induced using two MRSA strains, including an
intermediately vancomycin-resistant S. aureus
strain.Ceftobiprole had superior bactericidal activ-
ity as comparedwith vancomycin and linezolid [6].
Ceftobiprole was similarly active in rat and rabbit
endocarditis models using MRSA [17,18].
Mouse models have demonstrated the effective-
ness of ceftobiprole against pneumonia. Leukop-
enic mice were treated with subcutaneous
injections of ceftobiprole or ceftriaxone starting
3 h after infection with a S. pneumoniae strain that
was either penicillin-susceptible, penicillin-resist-
ant or penicillin ⁄ ceftriaxone ⁄ cefotaxime-resistant
[19]. Ten-day survival rates for ceftobiprole and
ceftriaxone were statistically significantly different
for only one penicillin-resistant strain, with a
difference favouring ceftobiprole (93% vs. 13%,
p <0.0001). Ceftobiprole required much lower
doses than ceftriaxone to achieve comparable
survival rates. In a similar murine system, ceftobi-
prole was as effective as cefepime and ceftriaxone
against infections caused by H. influenzae, Enterob-
acter cloacae, and non-ESBL-producing K. pneumo-
niae (44th ICAAC, B-1177).
The effectiveness of ceftobiprole in MRSA-
induced osteomyelitis, a particularly difficult
infection to treat, has been evaluated in rabbits.
Ceftobiprole administration resulted in 100%
clearance of the infection, with good drug penet-
ration into the bone matrix and marrow (45th
ICAAC, B-2007).
These data indicate that ceftobiprole is equiv-
alent or superior to comparators against MRSA,
intermediately vancomycin-resistant S. aureus
and non-ESBL-producing Gram-negative bacteria
in many classic animal models.
CONCLUSION
The microbiological profile of ceftobiprole shows
a distinct cephalosporin that acts as a potent
inhibitor of bacterial PBPs, including S. aureus
PBP2¢ and S. pneumoniae PBP2x. This potent inhi-
bition accounts for the superior in-vitro activity of
ceftobiprole against MRSA compared with other
available b-lactams, with in-vitro activity equiv-
alent to linezolid and vancomycin (MIC 2 mg ⁄L).
The activity of ceftobiprole against P. aeruginosa is
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similar to that of ceftazidime and piperacillin–
tazobactam. In addition, ceftobiprole has broad-
spectrum microbiological activity against many
other Gram-negative and Gram-positive patho-
gens. MIC values are typically £4 mg ⁄L for most
Gram-positive pathogens (including MRSA and
penicillin-resistant S. pneumoniae), for >90% of the
Enterobacteriaceae, and for >50% of P. aeruginosa
and Acinetobacter species.
Multiple classic animal models mirror this
equivalence or superiority to comparators against
a wide range of pathogens, including resistant
ones such as MRSA and penicillin-resistant
S. pneumoniae. The broad-spectrum in-vitro and
in-vivo activity suggests that ceftobiprole has
potential for empirical use in suspected Gram-
negative and Gram-positive infections, including
those due to resistant organisms such as MRSA.
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